Exhibit 99.1
Oragenics, Inc. Announces Appointment of Michael Sullivan as Chief Financial Officer
For Immediate Release
Tampa, FL (February 2, 2012) Oragenics, Inc. (OTCBB: ORNI) www.oragenics.com a nutraceutical company focused on oral care probiotics for humans and companion pets (the Company), announced the appointment of Michael Sullivan, CPA/MBA as the Companys Chief Financial Officer effective February 6, 2012. Mr. Sullivans will replace former CFO, Mr. Brian Bohunicky, who resigned January 27, 2012, in order to pursue other opportunities.
Most recently, Mr. Sullivan worked as the Group Financial Officer for the Investigative Services and Litigation Consulting Services segment of First Advantage Corporation, a firm specializing in talent acquisition solutions where he streamlined the employee recruitment process. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including: Utek Corporation, eANGLER, and HSN Direct International Limited. Mr. Sullivan is a Florida Certified Public Accountant, graduating from Florida State University with a Bachelor of Science in Accounting and a Master of Business Administration.
John N. Bonfiglio, Ph.D., Chief Executive Officer of Oragenics, stated, We look forward to having Mike Sullivan join the Oragenics team and support our vision of building a world-class probiotic and nutraceutical company.
Dr. Frederick Telling, Chairman of Oragenics, added We appreciate the years of dedicated service provided by Mr. Bohunicky to Oragenics and we wish him the best in his new endeavors.
About Oragenics, Inc.
Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The Companys proprietary products Evora and ProBiora3® are currently sold in over 20 countries. In addition, Oragenics has an exciting pipeline of therapeutic products targeting infectious disease.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Companys current views with respect to future events and financial performance. These forward-looking statements are based on managements beliefs and assumptions and information currently available. The words believe, expect, anticipate, intend, estimate, project and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond March 31, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
Corporate Contact: | Investor Contact: | |
Linda Loren | Jennifer K. Zimmons, Ph.D. | |
Marketing Director | Managing Director | |
Oragenics, Inc. | Cooper Global Communications, LLC | |
3000 Bayport Drive, Suite 685 | 245 Park Ave., 39th Floor | |
Tampa, Fl. 33607 | New York, NY 10176 | |
Tel: 813-527-1020 | Tel: 212-209-7360 | |
lloren@oragenics.com | jzimmons@cgc-us.com |